Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME.

J Clin Oncol. 2019 Jun 19:JCO1802141. doi: 10.1200/JCO.18.02141. [Epub ahead of print]

PMID:
31216228
2.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.

J Clin Oncol. 2019 Jun 2:JCO1900934. doi: 10.1200/JCO.19.00934. [Epub ahead of print]

PMID:
31154919
3.

Management strategies for early onset pulmonary events associated with brigatinib.

Camidge DR, Pabani A, Miller RM, Rizvi NA, Bazhenova L.

J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30371-5. doi: 10.1016/j.jtho.2019.04.028. [Epub ahead of print]

PMID:
31108247
4.

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell PD-L1 Expression in Patients with Advanced NCSLC Screened for the ATLANTIC Study.

Boothman AM, Scott M, Ratcliffe M, Whiteley J, Dennis PA, Wadsworth C, Sharpe A, Rizvi NA, Garassino MC, Walker J.

J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30360-0. doi: 10.1016/j.jtho.2019.04.025. [Epub ahead of print]

PMID:
31063864
5.

RNA-ALIS: Methodology for screening soluble RNAs as small molecule targets using ALIS affinity-selection mass spectrometry.

Rizvi NF, Nickbarg EB.

Methods. 2019 May 3. pii: S1046-2023(18)30386-4. doi: 10.1016/j.ymeth.2019.04.024. [Epub ahead of print]

PMID:
31059829
6.

Clinical and Quality of Life Outcomes Following Lung Volume Reduction Surgery.

Seadler B, Thuppal S, Rizvi N, Markwell S, Sawyer J, McCullough K, Crabtree T, Hazelrigg S.

Ann Thorac Surg. 2019 May 2. pii: S0003-4975(19)30606-X. doi: 10.1016/j.athoracsur.2019.03.089. [Epub ahead of print]

PMID:
31055037
7.

Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion.

Reed VA, Rizvi N.

Oncologist. 2019 Jun;24(6):730-734. doi: 10.1634/theoncologist.2018-0241. Epub 2019 Mar 21.

PMID:
30898888
8.

Procedural determinants of fluoroscopy time in patients undergoing cardiac catheterization.

Mujtaba SF, Saghir T, Sial JA, Rizvi NH.

Pak J Med Sci. 2019 Jan-Feb;35(1):166-171. doi: 10.12669/pjms.35.1.294.

10.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011. No abstract available.

PMID:
30753829
11.

A Novel Non-invasive Technique of Measuring Bilirubin Levels Using BiliCapture.

Rizvi MR, Alaskar FM, Albaradie RS, Rizvi NF, Al-Abdulwahab K.

Oman Med J. 2019 Jan;34(1):26-33. doi: 10.5001/omj.2019.05.

12.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
13.
14.

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R.

Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. [Epub ahead of print]

PMID:
30556813
15.

Role of medical Thoracoscopy in the Management of Multiloculated Empyema.

Sumalani KK, Rizvi NA, Asghar A.

BMC Pulm Med. 2018 Nov 29;18(1):179. doi: 10.1186/s12890-018-0745-y.

16.

Knowledge, attitude, and practices regarding infection control measures among medical students.

Sharif F, Khan A, Samad MA, Aijaz A, Asad I, Fatima M, Panni UY, Irshad A, Awais MB, Rizvi N, Hamid A.

J Pak Med Assoc. 2018 Jul;68(7):1065-1069.

17.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE 3rd, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, Boyd Z, Miley N, Flynn S, Leveque V, Shames DS, Ballinger M, Mocci S, Shankar G, Funke R, Hampton G, Sandler A, Amler L, Mellman I, Chen DS, Hegde PS.

Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126. doi: 10.1073/pnas.1802166115. Epub 2018 Oct 8.

18.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
19.

Identification of G-Quadruplex-Binding Inhibitors of Myc Expression through Affinity Selection-Mass Spectrometry.

Flusberg DA, Rizvi NF, Kutilek V, Andrews C, Saradjian P, Chamberlin C, Curran P, Swalm B, Kattar S, Smith GF, Dandliker P, Nickbarg EB, O'Neil J.

SLAS Discov. 2019 Feb;24(2):142-157. doi: 10.1177/2472555218796656. Epub 2018 Sep 11.

PMID:
30204533
20.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

21.

Managed successfully: Iatrogenic aortic dissection during primary percutaneous coronary intervention.

Kalwar MH, Sial JA, Saghir T, Rizvi NH, Qamar N.

J Pak Med Assoc. 2018 Apr;68(4):660-662.

22.

Interstitial Lung Diseases Misdiagnosed as Tuberculosis.

Akhter N, Rizvi NA.

Pak J Med Sci. 2018 Mar-Apr;34(2):338-341. doi: 10.12669/pjms.342.14407.

23.

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N.

J Thorac Oncol. 2018 Sep;13(9):1363-1372. doi: 10.1016/j.jtho.2018.05.015. Epub 2018 May 23.

PMID:
29802888
24.

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.

Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA.

J Thorac Oncol. 2018 Nov;13(11):1733-1742. doi: 10.1016/j.jtho.2018.05.004.

PMID:
29775807
25.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3. Erratum in: Cancer Cell. 2019 Feb 11;35(2):329.

26.

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S.

BMC Cancer. 2018 Apr 12;18(1):413. doi: 10.1186/s12885-018-4200-5.

27.

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.

Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar M.

Clin Cancer Res. 2018 Jun 15;24(12):2749-2757. doi: 10.1158/1078-0432.CCR-17-1775. Epub 2018 Mar 20.

28.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
29.

Application of BiPAP through Endotracheal Tube in Comatose Patients with COPD Exacerbation.

Akhter N, Rizvi NA.

Pak J Med Sci. 2017 Nov-Dec;33(6):1444-1448. doi: 10.12669/pjms.336.13972.

30.

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S.

BMC Cancer. 2018 Feb 27;18(1):225. doi: 10.1186/s12885-018-4134-y. Erratum in: BMC Cancer. 2018 Apr 12;18(1):413.

31.

Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry.

Rizvi NF, Howe JA, Nahvi A, Klein DJ, Fischmann TO, Kim HY, McCoy MA, Walker SS, Hruza A, Richards MP, Chamberlin C, Saradjian P, Butko MT, Mercado G, Burchard J, Strickland C, Dandliker PJ, Smith GF, Nickbarg EB.

ACS Chem Biol. 2018 Mar 16;13(3):820-831. doi: 10.1021/acschembio.7b01013. Epub 2018 Feb 14.

PMID:
29412640
32.

Combining chemotherapy with PD-1 blockade in NSCLC.

Mathew M, Enzler T, Shu CA, Rizvi NA.

Pharmacol Ther. 2018 Jun;186:130-137. doi: 10.1016/j.pharmthera.2018.01.003. Epub 2018 Jan 31. Review.

PMID:
29352857
34.

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA.

Science. 2018 Feb 2;359(6375):582-587. doi: 10.1126/science.aao4572. Epub 2017 Dec 7.

35.

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.

Rizvi NA, Peters S.

N Engl J Med. 2017 Nov 16;377(20):1986-1988. doi: 10.1056/NEJMe1711430. No abstract available.

PMID:
29141165
36.

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD.

Nature. 2017 Nov 23;551(7681):517-520. doi: 10.1038/nature24473. Epub 2017 Nov 8.

37.

RNA as a small molecule druggable target.

Rizvi NF, Smith GF.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5083-5088. doi: 10.1016/j.bmcl.2017.10.052. Epub 2017 Oct 23. Review.

PMID:
29097169
38.

Barriers or gaps in implementation of misoprostol use for post-abortion care and post-partum hemorrhage prevention in developing countries: a systematic review.

Samnani AABA, Rizvi N, Ali TS, Abrejo F.

Reprod Health. 2017 Oct 27;14(1):139. doi: 10.1186/s12978-017-0383-5. Review.

39.

Management of community acquired pneumonia by Family Physicians.

Akhter S, Rizvi N, Bhura S, Warraich UA.

Pak J Med Sci. 2017 Jul-Aug;33(4):783-787. doi: 10.12669/pjms.334.12577.

40.

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.

Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A.

Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12.

41.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.

J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.

42.

Primary Pleural Epitheliod Hemangioendothelioma with Lung Involvement.

Siraj S, Akhter S, Rizvi N.

J Coll Physicians Surg Pak. 2017 Sep;27(9):S120-S121. doi: 281.

PMID:
28969747
43.

Who teaches science to nurses?

Rizvi N.

J Pak Med Assoc. 2017 Jul;67(7):1013-1018.

44.

Prevalence of Hepatitis B core antibodies with negative Hepatitis B surface antigen in dialysis and chronic kidney disease patients.

Tarif N, Riaz MM, Sabir O, Akhter R, Rafique K, Rizvi N.

Saudi J Kidney Dis Transpl. 2017 Jul-Aug;28(4):869-873.

45.

Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan.

Zaidi SMA, Haseeb A, Habib SS, Malik A, Khowaja S, SaifUllah N, Rizvi N.

BMC Res Notes. 2017 Jul 25;10(1):313. doi: 10.1186/s13104-017-2633-6.

46.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E.

J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.

47.

Barriers in adopting blended learning in a private university of Pakistan and East Africa: faculty members' perspective.

Rizvi NF, Gulzar S, Nicholas W, Nkoroi B.

Mhealth. 2017 May 5;3:18. doi: 10.21037/mhealth.2017.04.04. eCollection 2017.

48.

The use of immunotherapy in the first-line treatment of lung cancer.

Rizvi NA.

Clin Adv Hematol Oncol. 2017 Mar;15(3):190-192. No abstract available.

PMID:
28398273
49.

Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.

Javaid A, Hasan R, Zafar A, Chaudry MA, Qayyum S, Qadeer E, Shaheen Z, Agha N, Rizvi N, Afridi MZ, Chima MK, Khan AR, Ghafoor A, Khan S, Awan SR, Akhtar S, Choudry K, Iqbal ZH, Ansarie M, Ahmad N.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):303-308. doi: 10.5588/ijtld.16.0444.

PMID:
28225340
50.

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2017 Feb 17;7:41197. doi: 10.1038/srep41197. No abstract available.

Supplemental Content

Support Center